MESOTELIOMA . KEYTRUDA ( PEMBROLIZUMAB BY MERCK ) POSIBLE NUEVO TRATAMIENTO . En la FASE III los Pacientes Experimentaron una Supervivencia General Significativamente Mejor en Comparación con los Tratados con Quimioterapia Sola .

Phase III Trial Reports Chemoimmunotherapy Is Superior To Chemotherapy Alone in Malignant Pleural Mesothelioma .

Patients With Malignant Pleural MESOTELIOMA who were treated with a CHEMOIMMUNOTHERAPY Regimen containing the Immune Checkpoint Inhibitor PEMBROLIZUMAB Experienced Significantly Improved OVERALL SURVIVAL Compared With Those Treated With CHEMOTHERAPY Alone, with Acceptable Tolerability, According to Findings From a PHASE III Study Discussed at the 2023 Best of ASCO Seattle .

In a session on local or regional Non–Small Cell Lung Cáncer (NSCLC), Christina S. Baik, MD, MPH, reviewed Results from a PHASE III trial of PLATINUM/Pemetrexed with or without PEMBROLIZUMAB in Patients With Malignant Pleural MESOTELIOMA .

 In the study (a collaboration among the Canadian Cancer Trials Group, the National Cancer Institute of Naples, and the French Cooperative Thoracic Intergroup), the improvement in survival seen with the addition of PEMBROLIZUMAB to CHEMOTHERAPY was evident in patients with both PD-L1–positive and PD-L1–negative tumors . ...